Alpharadin shows 2.8-month survival benefit in mCRPC

The investigational radioisotope radium-233 chloride (Alpharadin) has shown a small but clinically significant overall survival benefit in the treatment of men with symptomatic, metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …